| General information | Literature | Expression | Regulation | Variant | Interaction |
|
Basic Information |
|
|---|---|
Gene ID | 5241 |
Name | PGR |
Synonymous | NR3C3|PR;progesterone receptor;PGR;progesterone receptor |
Definition | nuclear receptor subfamily 3 group C member 3 |
Position | 11q22-q23 |
Gene Type | protein-coding |
Gene Regulation: | Upstream microRNAs Transcription Factors Post Transcriptional Modification From dbPTM Methylation Profile From DiseaseMeth database |
Experimentally verified miRNA from miRTarBase [Top] | |||
 |
Transcription Factors [Top] |
|
Regulation From TransFac database |
PR B(h) --> LYS(c) (DNA binding; transregulation). | PR B(h) + Cdc25B(h) <==> PR B(h):Cdc25B(h) (binding) | PR B(h) + ATP --cyclinA(h):Cdk2(h)--> PR B(h){p} + ADP (phosphorylation) | Hsp90(h) + PR B(h) <==> Hsp90(h):PR B(h) (binding). | PR A(h) + PR B(h) <==> PR A(h):PR B(h) (binding). | PR B(h) + PR B(h) <==> PR B(h):PR B(h) (binding). | PR B(h) + TAF(II)110(d) <==> PR B(h):TAF(II)110(d) (binding). | PR B(h) --> IGFBP1(h) (DNA binding; transactivation). | PR B(h) --> GNRHR(h) (DNA binding; transregulation). | PR B(h) + SET-isoform2(h) <==> PR B(h):SET-isoform2(h) (binding) | SRC3(m.s.) + PR B(h) <==> SRC3(m.s.):PR B(h) (binding) | PR B(h) + DP97-xbb2(h) <==> PR B(h):DP97-xbb2(h) (binding) | batf3(r) + PR B(h) <==> batf3(r):PR B(h) (binding) | batf3(h) + PR B(h) <==> batf3(h):PR B(h) (binding) | jdp2(r) + PR B(h) <==> jdp2(r):PR B(h) (binding) | jdp2(h) + PR B(h) <==> jdp2(h):PR B(h) (binding) | PR B(h) --> C/EBPalpha(m) (increase of abundance) | PR B(h) --> Cebpa(m) (transactivation) | PR B(h) --/ HDAC1(m) (decrease of abundance) | PR B(h) + PSF(gl) <==> PR B(h):PSF(gl) (binding) | PSF-isoform1(h) + PR B(h) <==> PSF-isoform1(h):PR B(h) (binding) | PR B(h) + PSF(h) <==> PR B(h):PSF(h) (binding) | PR B(h) --26S proteasome(gl)--> protein remnants (degradation) | PR B(h) --> prl(h) (transactivation) | PR B(h) + NF-IL6-3(h) <==> PR B(h):NF-IL6-3(h) (binding) | NF-IL6-1(h) + PR B(h) <==> NF-IL6-1(h):PR B(h) (binding) | PR B(h) + DAX1(h) <==> PR B(h):DAX1(h) (binding) | PR B(h) + DAX1(h) <==> PR B(h):DAX1(h) (binding) | brca1(h) + PR B(h) <==> brca1(h):PR B(h) (binding) | PR B(h) --> c-myc(h) (DNA binding). | cyclinA(m.s.) + PR B(h) <==> cyclinA(m.s.):PR B(h) (binding) | PR B(h) + cyclinA(h) <==> PR B(h):cyclinA(h) (binding) | SRC-1(m.s.) + PR B(h) <==> SRC-1(m.s.):PR B(h) (binding) | PR B(h) + ATP --> PR B(h){pS294} + ADP (phosphorylation) | PR B(h) --> BCL2(h) (transactivation) | PR B(h) --/ Csn2(r) (DNA binding; transrepression). | PGR(h) --> PR B(h) (expression). | estradiol --> PR B(h) (increase of abundance) | TR2(h) --/ PR B(h) (decrease of abundance) | PR A(h) --> LYS(c) (DNA binding; transregulation). | PR A(h) + ATP --cyclinA(h):Cdk2(h)--> PR A(h){p} + ADP (phosphorylation) | PR A(h) + PR B(h) <==> PR A(h):PR B(h) (binding). | Hsp90(h) + PR A(h) <==> Hsp90(h):PR A(h) (binding). | PR A(h) --> IGFBP1(h) (DNA binding; transactivation). | PR A(h) --/ GNRHR(h) (DNA binding; transrepression). | batf3(r) + PR A(h) <==> batf3(r):PR A(h) (binding) | batf3(h) + PR A(h) <==> batf3(h):PR A(h) (binding) | jdp2(r) + PR A(h) <==> jdp2(r):PR A(h) (binding) | jdp2(h) + PR A(h) <==> jdp2(h):PR A(h) (binding) | TIF1a-short(h) + PR A(h) <==> TIF1a-short(h):PR A(h) (binding) | PSF(h) + PR A(h) <==> PSF(h):PR A(h) (binding) | PSF-isoform1(h) + PR A(h) <==> PSF-isoform1(h):PR A(h) (binding) | PR A(h) --26S proteasome(gl)--> protein remnants (degradation) | PR A(h) --> prl(h) (transactivation) | NF-IL6-3(h) + PR A(h) <==> NF-IL6-3(h):PR A(h) (binding) | PR A(h) + NF-IL6-1(h) <==> PR A(h):NF-IL6-1(h) (binding) | PR A(h) + DAX1(h) <==> PR A(h):DAX1(h) (binding) | PR A(h) + SMRT(h) <==> PR A(h):SMRT(h) (binding) | brca1(h) + PR A(h) <==> brca1(h):PR A(h) (binding) | PR A(h) --> c-myc(h) (DNA binding). | cyclinA(m.s.) + PR A(h) <==> cyclinA(m.s.):PR A(h) (binding) | PR A(h) + cyclinA(h) <==> PR A(h):cyclinA(h) (binding) | PR A(h) --> BCL2(h) (transactivation) | PR A(h) --/ Csn2(r) (DNA binding; transrepression). | PGR(h) --> PR A(h) (expression). | estradiol --> PR A(h) (increase of abundance) | TR2(h) --/ PR A(h) (decrease of abundance) | PR(h) + sumo1(m.s.) --> PR(h){sumoK388} (sumoylation) | PR(h) + MVP(h) <==> PR(h):MVP(h) (binding) | PR(h) + PNRC2(h) <==> PR(h):PNRC2(h) (binding) | PR(h) --> HLA-G(h) (DNA binding). | PR(h) --> BCL2(h) (DNA binding; transactivation). | PR(h) + HSJ2(h) <==> PR(h):HSJ2(h) (binding) | PR(h) + HSPA4(h) + HSJ2(h) <==> PR(h):HSPA4(h):HSJ2(h) (binding) | TEBP(h) + HSPA4(h) + STIP1(h) + PR(h) + Hsp90-alpha(h) <==> TEBP(h):HSPA4(h):STIP1(h):PR(h):Hsp90-alpha(h) (binding) | PR(h) + HSPA4(h) + Hsp40(m.s.) <==> PR(h):HSPA4(h):Hsp40(m.s.) (binding) | HSPA4(h) + PR(h) <==> HSPA4(h):PR(h) (binding) | PR(h) --> FKBP5(h) (DNA binding). | PGR(h) --> PR(h) (expression). | estradiol --> PR(h) (increase of abundance) | p65PAK(h) --> PR(h) (increase of abundance) | TR2(h) --/ PR(h) (decrease of abundance) | ARA70(m.s.) --> PR(h) (activation) | TIF2(m.s.) --> PR(h) (activation) |
|---|
Post Transcriptional Modification [Top] | |||
|
Location (AA) |
PTM type |
Literature |
Database |
20 | Phosphoserine. | Swiss-Prot 53.0 | 25 | Phosphoserine; by CDK2; in vitro. | Swiss-Prot 53.0 | 41 | Phosphothreonine; by CK. | Swiss-Prot 53.0 | 102 | Phosphoserine. | Swiss-Prot 53.0 | 130 | Phosphoserine. | Swiss-Prot 53.0 | 162 | Phosphoserine. | Swiss-Prot 53.0 | 190 | Phosphoserine. | Swiss-Prot 53.0 | 213 | Phosphoserine. | Swiss-Prot 53.0 | 227 | Phosphoserine; by CK. | Swiss-Prot 53.0 | 232 | Phosphoserine; by CK. | Swiss-Prot 53.0 | 345 | Phosphoserine. | Swiss-Prot 53.0 | 430 | Phosphothreonine; by CDK2; in vitro. | Swiss-Prot 53.0 | 552 | Phosphoserine; by CK. | Swiss-Prot 53.0 | 554 | Phosphoserine; by CDK2; in vitro. | Swiss-Prot 53.0 | 676 | Phosphoserine. | Swiss-Prot 53.0 | 793 | Phosphoserine; by CK. | Swiss-Prot 53.0 | 213 | Phosphoserine (CDK2) | 11110801 | Phospho.ELM 6.0 | 676 | Phosphoserine (CDK2) | 11110801 | Phospho.ELM 6.0 | 345 | Phosphoserine | 11110801 | Phospho.ELM 6.0 | 102 | Phosphoserine | 11110801 | Phospho.ELM 6.0 | 130 | Phosphoserine | 11110801 | Phospho.ELM 6.0 | 20 | Phosphoserine | 11110801 | Phospho.ELM 6.0 | 294 | Phosphoserine (MAPK1;MAPK3) | 10655479;10628747;12529413 | Phospho.ELM 6.0 | 190 | Phosphoserine (CDK2) | 11110801;9171245 | Phospho.ELM 6.0 | 162 | Phosphoserine (CDK2) | 11110801;9171245 | Phospho.ELM 6.0 | 400 | Phosphoserine (CDK2) | 11110801;9171245 | Phospho.ELM 6.0 |
|---|---|---|---|
Methylation Profile [Top] | ||
|
Chromosome |
Location |
Source |
|---|---|---|
chr11 |
Promoter: 100505965 - 100507965 | GoldenGate_Methylation_Cancer_Panel_I |
chr11 |
Promoter: 100505965 - 100507965 | PMID:15178346 |
chr11 |
Promoter: 100505965 - 100507965 | PMID:11895880 |
chr11 |
Promoter: 100505965 - 100507965 | PMID:15639718 |
chr11 |
Promoter: 100505965 - 100507965 | PMID:12899921 |
chr11 |
Promoter: 100505965 - 100507965 | PMID:15172987 |
chr11 |
Promoter: 100505965 - 100507965 | PMID:11196205 |